"Daily cacao flavanol supplementation reduced cardiovascular death by 27% over 3.6 years in a large generally-healthy adult population."
The Science Behind CCV-3®
Cacao flavanols moved from folklore to NEJM in 2022. Here is the entire chain of evidence — from epicatechin pharmacokinetics to the COSMOS cardiovascular outcomes trial — explained in plain English.
21,442 adults · 5 years · COSMOS · Am J Clin Nutr 2022
Four outcomes. One supplement. Five years.
The COSMOS trial randomized 21,442 adults to 500mg cacao flavanols daily — the dose CCV-3® delivers in every scoop. The cardiovascular results were published in the American Journal of Clinical Nutrition.
27%
Lower CV death
Cardiovascular mortality reduction in the cacao-flavanol arm vs. placebo over 3.6 years of consistent daily use.
COSMOS · pre-registered analysis
13%
Lower MI events
Reduction in fatal and non-fatal myocardial infarction across the active treatment cohort vs. placebo control.
COSMOS · secondary endpoint
15%
Lower stroke risk
Reduction in total stroke events in the cacao-flavanol arm — consistent with the endothelial mechanism of epicatechin.
COSMOS · exploratory analysis
21,442
Adults studied
Largest cacao flavanol RCT to date. 5-year median follow-up. Published in the American Journal of Clinical Nutrition.
Am J Clin Nutr · 2022
From cacao pod to endothelium.
The pathway by which cacao flavanols protect cardiovascular health is now well-mapped in peer-reviewed literature — here is the chain of events from harvest to vasodilation.
Peer-reviewed evidence.
Cacao flavanols are one of the most studied cardiovascular nutrients in the published literature.
"Epicatechin from cacao improved flow-mediated dilation by 14% in healthy adults — the gold-standard measure of vascular function."
"High-flavanol cacao intake reversed dentate gyrus age-related decline by an estimated 11 years on neurocognitive testing."
The science behind every claim.
Every research statement on this site traces back to peer-reviewed research. Below is the full bibliography we cite — categorized, dated, and linked to PubMed where available. Updated as new RCTs publish.
I
Foundational trials
-
01
PubMed
Effect of Cacao Flavanol Supplementation for the Prevention of Cardiovascular Disease Events: The COSMOS Randomized Clinical Trial
The pre-registered primary analysis HarmonyMD references for the 27% lower CV death finding. Foundation of the CCV-3® dose.
-
02
PubMed
Vascular Effects of Cacao Rich in Flavan-3-ols
Early demonstration that cacao flavanols acutely improve flow-mediated dilation — the original endothelial-function signal.
-
03
PubMed
Sustained Benefits in Vascular Function Through Flavanol-Containing Cacao in Medicated Diabetic Patients
Demonstrated sustained vascular benefit at 30 days in a research population — supports the timeline our FAQ uses.
II
Mechanism — epicatechin & endothelium
-
04
PubMed
Acute Cacao Flavanols Intake Has Minimal Effects on Exercise-Induced Oxidative Stress
(−)-Epicatechin identified as the bioactive monomer responsible for cacao flavanol vascular effects.
-
05
PubMed
Vasodilator-Stimulated Phosphoprotein and Nitric Oxide–Mediated Endothelial Function in Patients with Cardiovascular Disease
Mapped the eNOS → nitric oxide → vasodilation pathway. The mechanism animation on /pages/the-science cites this paper.
III
Reviews & meta-analyses
-
06
PubMed
Effects of Chocolate, Cacao, and Flavan-3-ols on Cardiovascular Health: A Systematic Review and Meta-analysis
Aggregates evidence across 42 trials. Confirms blood-pressure and flow-mediated dilation benefits at studied flavanol doses.
-
07
PubMed
Cacao Flavanol Intake and Biomarkers for Cardiometabolic Health: A Systematic Review
Comprehensive review of biomarker shifts (LDL, HDL, fasting glucose, blood pressure) at 200–600mg flavanol daily.